Last updated on July 2019
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Ductal Carcinoma In Situ | Squamous cell carcinoma | Solid Tumors | melanoma | Mycosis Fungoides | Human Papillomavirus-Related Malignant Neoplasm | Merkel cell carcinoma | Sarcoma | skin cancer | Breast Cancer
-
Age: Between 18 - 100 Years
-
Gender: Male or Female
Inclusion Criteria:
- Histologically or cytologically documented, injectable cancer lesion (limited to solid tumors and mycosis fungoides)
- Adequate renal function
- Adequate coagulation function
- Adequate hepatic function
- Disease that has progressed on standard therapy or for whom there is no other therapy option available
Exclusion Criteria:
- Central nervous system involvement
- Significant cardiovascular disease
- Active autoimmune disease
- Active hepatitis B or C or a history of HIV infection
- Uncontrolled infection
- History of hemolytic anemia or bleeding diathesis